FAQ: HeartBeam Inc.'s Investor Conference Participation and Technology Overview

What is the main announcement in this content?

HeartBeam Inc. announced that CEO Robert Eno and CFO Timothy Cruickshank will attend and present at three investor conferences in September 2025: MDB Investor Summit 2025, HRX Live 2025, and the H.C. Wainwright 27th Annual Global Investment Conference.

What will HeartBeam executives present at these conferences?

They will provide updates on the company’s commercialization progress and demonstrate the FDA-cleared HeartBeam System, which is a cable-free, credit card-sized device that collects 3D ECG signals for arrhythmia assessment.

What makes HeartBeam’s technology unique?

HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG, designed for portable use outside medical facilities.

What regulatory approvals has HeartBeam received?

The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and their 12-Lead ECG synthesis software is currently under FDA review.

Why is this technology significant for cardiac care?

It enables physicians to identify cardiac health trends and acute conditions outside medical facilities, allowing for remote monitoring and directing patients to appropriate care, thus redefining cardiac health management.

Where can investors find more information about HeartBeam?

The latest news and updates are available in the company’s newsroom at https://ibn.fm/BEAT, and the full press release can be viewed at https://ibn.fm/iTYHV.

What intellectual property does HeartBeam hold?

The company holds over 20 issued patents related to their technology enablement, protecting their innovative 3D ECG platform.

How does this technology benefit patients?

It provides actionable heart intelligence through portable devices that can be used wherever the patient is, enabling convenient cardiac monitoring and early detection of conditions without requiring hospital visits.